company background image
47M logo

MedMira DB:47M Stock Report

Last Price

€0.073

Market Cap

€46.3m

7D

46.0%

1Y

18.7%

Updated

02 Jan, 2025

Data

Company Financials

47M Stock Overview

A biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally. More details

47M fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

MedMira Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for MedMira
Historical stock prices
Current Share PriceCA$0.073
52 Week HighCA$0.08
52 Week LowCA$0.043
Beta10.41
1 Month Change56.99%
3 Month Change50.52%
1 Year Change18.70%
3 Year Change-50.37%
5 Year Change1,725.00%
Change since IPO-90.52%

Recent News & Updates

Recent updates

Shareholder Returns

47MDE Medical EquipmentDE Market
7D46.0%-1.6%0.3%
1Y18.7%-6.5%8.4%

Return vs Industry: 47M exceeded the German Medical Equipment industry which returned -6.5% over the past year.

Return vs Market: 47M exceeded the German Market which returned 8.4% over the past year.

Price Volatility

Is 47M's price volatile compared to industry and market?
47M volatility
47M Average Weekly Movement25.7%
Medical Equipment Industry Average Movement6.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.8%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 47M's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 47M's weekly volatility has increased from 20% to 26% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993n/aHermes Chanmedmira.com

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and REVEALCOVID-19 and Reveal G4 HIV tests.

MedMira Inc. Fundamentals Summary

How do MedMira's earnings and revenue compare to its market cap?
47M fundamental statistics
Market cap€46.33m
Earnings (TTM)-€2.60m
Revenue (TTM)€241.17k

222.5x

P/S Ratio

-20.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
47M income statement (TTM)
RevenueCA$356.43k
Cost of RevenueCA$1.02m
Gross Profit-CA$662.63k
Other ExpensesCA$3.18m
Earnings-CA$3.85m

Last Reported Earnings

Oct 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0053
Gross Margin-185.91%
Net Profit Margin-1,079.18%
Debt/Equity Ratio-67.4%

How did 47M perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:33
End of Day Share Price 2025/01/02 00:00
Earnings2024/10/31
Annual Earnings2024/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MedMira Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution